4-(咪唑-1-基甲基)苯甲酸 | 94084-75-0

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(咪唑-1-基甲基)苯甲酸
• 英文名称: 4-(1H-imidazol-1-ylmethyl)benzoic acid
• 英文别名: p-(1H-imidazole-1-ylmethyl)benzoic acid；4-(imidazol-1-ylmethyl)benzoic acid；4-imidazol-1-ylmethyl-benzoic acid
• CAS: 94084-75-0
• 化学式: C₁₁H₁₀N₂O₂
• mdl: MFCD09736739
• 分子量: 202.213
• InChiKey: PBTHRDAMTTXZFL-UHFFFAOYSA-N

物化性质

• 熔点：
  267-268 °C(Solv: methanol (67-56-1); water (7732-18-5))
• 沸点：
  441.4±28.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933290090
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-(咪唑-1-基甲基)苯甲酸 在 硫酸 、 一水合肼 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 4-(1H-imidazol-1-ylmethyl)benzohydrazide
  参考文献：
  名称：

  Aromatic hydrazides as specific inhibitors of bovine serum amine oxidase

  摘要：

  New hydrazides were synthesized in search for specific inhibitors of bovine serum amine oxidase: a series of benzoic and phenylacetic acid hydrazides containing the 1H-imidazol-1-yl or the 1H-imidazol-1-ylmethyl group as (o, m, p)-substituent in the phenyl ring; an analogous series of p-substituted phenylhydrazides with 5 or 6-membered heterocyclic ring as substituent, and a series of similar phenylpropionic hydrazides. The longer and more flexible phenylacetic hydrazides, and to a somewhat lesser extent the phenylpropionic ones, were better specific inhibitors of bovine serum amine oxidase than the benzoic hydrazides, which were also bound by the enzyme with high affinity, but at a slow rate. Derivatives with p- and m -substituents were more reactive than the o-substituted ones. The chemical nature of the substituent was less important than its position in the phenyl ring and the presence of methylene spacers. These data point to the presence of a hydrophobic site at short distance from the protein carbonyl cofactor, so that simultaneous interaction of the 2 ends of the inhibitor molecule can occur at the 2 sites. The presence of the hydrophobic site was confirmed by the capability of some molecule deprived of the hydrazidic group to act as mild inhibitors. All hydrazides were less reactive by 2-3 orders of magnitude towards pig kidney diamine oxidase and FAD-dependent monoamine oxidase from rat brain mitochondria, while the other compounds showed similar inhibition power against all proteins. The specificity for the bovine enzyme seems therefore to be related to the concerted action of the 2 moieties of the inhibitor molecule.

  DOI：

  10.1016/0223-5234(92)90005-l
• 作为产物：
  描述：

  4-氯甲基苯甲酰氯 在 水 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 4-(咪唑-1-基甲基)苯甲酸
  参考文献：
  名称：

  Cardiotonic agents. 2. (Imidazolyl)aroylimidazolones, highly potent and selective positive inotropic agents

  摘要：

  A series of 4-alkyl-1,3-dihydro-5-[(1H-imidazolyl)benzoyl]-2H-imidazol-2-ones 9 was synthesized and evaluated in vitro for positive inotropic and cyclic AMP phosphodiesterase inhibitory activity. A wide range of inotropic and enzyme-inhibitory potencies was observed, substitution on the imidazolyl moiety being the major determinant of activity. The 4-ethyl-5-[4-(1H-imidazol-1-yl)benzoyl] congener 9g exhibited the highest potency in vitro. Incorporation of a methyl group at the imidazolyl 2-position gave 9h, which was less potent but remarkably selective in vivo for positive inotropic effects over heart rate and hypotensive effects.

  DOI：

  10.1021/jm00391a013

文献信息

• Sulfonamide derivatives, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06359134B1

  公开（公告）日：2002-03-19

  The present invention provides compounds which specifically inhibit FXa, which are effective when orally administered and which are useful as a safe medicine for the prevention or treatment of diseases caused by thrombus or infarction. Compounds of this invention are piperazinones of the formula: wherein R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; the ring A is an optionally substituted divalent nitrogen-containing heterocyclic group, in addition to being substituted by the group of the formula: and the group of the formula: Y is an optionally substituted divalent hydrocarbon group or an optionally substituted divalent heterocyclic group; X is a direct bond or an optionally substituted alkylene chain; Z is (1) an amino group substituted with an optionally substituted hydrocarbon group, (2) an optionally substituted imino group or (3) an optionally substituted nitrogen-containing heterocyclic group; provided that when X is a direct bond and Z is an optionally substituted 6-membered nitrogen-containing aromatic heterocyclic group, Y is an optionally substituted divalent hydrocarbon group or an optionally substituted divalent unsaturated heterocyclic group; or a salt thereof.

  本发明提供了一种化合物，该化合物特异性地抑制FXa，口服给药有效，并且用作预防或治疗由血栓或梗死引起的疾病的药物是安全的。本发明的化合物是哌嗪酮的公式： 其中R1是可选地取代的烃基或可选地取代的杂环基；环A是除了被公式：的基团取代的之外的可选地取代的二价含氮杂环基： 和公式的基团： Y是可选地取代的二价烃基或可选地取代的二价杂环基；X是直接键或可选地取代的亚烷基链；Z是（1）与可选地取代的烃基取代的氨基，（2）可选地取代的亚氨基或（3）可选地取代的含氮杂环基；当X是直接键并且Z是可选地取代的6-成员含氮芳香杂环基时，Y是可选地取代的二价烃基或可选地取代的二价不饱和杂环基；或其盐。
• Benzamide nitriles
  申请人：——

  公开号：US20040248949A1

  公开（公告）日：2004-12-09

  Compounds of the formula (I) 1 wherein m, n, A, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as described herein, together with methods for making the compounds and using the compounds for treatment of diseases or conditions mediated by Cathepsin K.

  式（I）的化合物 其中m，n，A，R1，R2，R3，R4，R5和R6如本文所述，以及制备这些化合物的方法以及利用这些化合物治疗由Cathepsin K介导的疾病或症状。
• Indolinones having kinase-inhibiting activity
  申请人：Boehringer Ingelheim Pharma KG

  公开号：US06043254A1

  公开（公告）日：2000-03-28

  The present invention relates to indolinones of general formula ##STR1## wherein R.sub.1 to R.sub.3 are defined in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on various kinases and cycline/CDK complexes and on the proliferation of various tumour cells, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

  本发明涉及一般式##STR1##中R.sub.1至R.sub.3的定义如权利要求1所述，其异构体和盐，特别是具有有价值的药理特性的生理上可接受的盐，特别是对各种激酶和cycline/CDK复合物以及各种肿瘤细胞增殖具有抑制作用的盐，含有这些化合物的药物组合物，它们的用途和制备它们的方法。
• Discovery of an MLLT1/3 YEATS Domain Chemical Probe
  作者：Moses Moustakim、Thomas Christott、Octovia P. Monteiro、James Bennett、Charline Giroud、Jennifer Ward、Catherine M. Rogers、Paul Smith、Ioanna Panagakou、Laura Díaz-Sáez、Suet Ling Felce、Vicki Gamble、Carina Gileadi、Nadia Halidi、David Heidenreich、Apirat Chaikuad、Stefan Knapp、Kilian V. M. Huber、Gillian Farnie、Jag Heer、Nenad Manevski、Gennady Poda、Rima Al-awar、Darren J. Dixon、Paul E. Brennan、Oleg Fedorov

  DOI：10.1002/anie.201810617

  日期：2018.12.10

  YEATS domain (YD) containing proteins are an emerging class of epigenetic targets in drug discovery. Dysregulation of these modified lysine-binding proteins has been linked to the onset and progression of cancers. We herein report the discovery and characterisation of the first small-molecule chemical probe, SGC-iMLLT, for the YD of MLLT1 (ENL/YEATS1) and MLLT3 (AF9/YEATS3). SGC-iMLLT is a potent and

  包含YEATS域（YD）的蛋白质是药物发现中新兴的表观遗传学目标。这些修饰的赖氨酸结合蛋白的失调与癌症的发生和发展有关。我们在此报告了针对MLLT1（ENL / YEATS1）和MLLT3（AF9 / YEATS3）的YD的第一个小分子化学探针SGC-iMLLT的发现和表征。SGC-iMLLT是一种有效且选择性的MLLT1 / 3-组蛋白相互作用抑制剂。观察到对其他人类YD蛋白（YEATS2 / 4）和溴结构域具有出色的选择性。此外，我们的探针显示了MLLT1和MLLT3的细胞靶标接合。还报道了具有MLLT1 YD的第一个小分子X射线共晶体结构。
• [EN] DEGRADABLE IMIDAZOLIUM OLIGOMER AND POLYMER FOR ANTIMICROBIAL APPLICATIONS<br/>[FR] OLIGOMÈRE D'IMIDAZOLIUM DÉGRADABLE ET POLYMÈRE POUR APPLICATIONS ANTIMICROBIENNES
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2019004940A1

  公开（公告）日：2019-01-03

  The present invention relates to an imidazolium oligomer of formula (I) and an imidazolium oligomer or a polymer of formula (II) where the various groups are as defined in the specification. The present invention also relates to the methods for their preparation, antimicrobial composition, antimicrobial gel containing these oligomers and/or polymers of Formula (I) and (II), and uses of these oligomers and/or polymers in the treatment of a microbial infection or disease.

  本发明涉及公式（I）的咪唑鎓寡聚物以及公式（II）的咪唑鎓寡聚物或聚合物，其中各种基团如规范中所定义。本发明还涉及它们的制备方法，抗菌组合物，含有这些寡聚物和/或公式（I）和（II）的聚合物的抗菌凝胶，以及这些寡聚物和/或聚合物在治疗微生物感染或疾病中的用途。